Hydrochloric Acid → N-{4-Methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(pentafluoro-lambda6-sulphanyl)-5-(piperazin-1-yl)benzamide
반응식
CC1C=CC(N)=CC=1N1C2N(N=C(C3C=NC=CC=3)C=2)C=C1.C(OC(N1CCN(C2C=C(C=C(S(F)(F)(F)(F)F)C=2)C(O)=O)CC1)=O)(C)(C)C.[CH3:51][C:52]1[CH:57]=[CH:56][C:55]([NH:58][C:59]([C:61]2[CH:62]=[C:63]([N:73]3[CH2:78][CH2:77][N:76](C(OC(C)(C)C)=O)[CH2:75][CH2:74]3)[CH:64]=[C:65]([S:67]([F:72])([F:71])([F:70])([F:69])[F:68])[CH:66]=2)=[O:60])=[CH:54][C:53]=1[N:86]1[C:93]2[N:89]([N:90]=[C:91]([C:94]3[CH:95]=[N:96][CH:97]=[CH:98][CH:99]=3)[CH:92]=2)[CH:88]=[CH:87]1.Cl>O1CCOCC1.CO>[CH3:51][C:52]1[CH:57]=[CH:56][C:55]([NH:58][C:59](=[O:60])[C:61]2[CH:62]=[C:63]([N:73]3[CH2:74][CH2:75][NH:76][CH2:77][CH2:78]3)[CH:64]=[C:65]([S:67]([F:71])([F:70])([F:69])([F:72])[F:68])[CH:66]=2)=[CH:54][C:53]=1[N:86]1[C:93]2[N:89]([N:90]=[C:91]([C:94]3[CH:95]=[N:96][CH:97]=[CH:98][CH:99]=3)[CH:92]=2)[CH:88]=[CH:87]1참가 물질
반응물 4
생성물 1
시약·촉매·용매 2
반응 조건
- 온도
- 80 °C
실험 절차
120 mg (0.42 mmol) of the compound of Example 6A and 179 mg (0.42 mmol) of the compound of Example 16A were reacted and worked up analogously to the procedure of Example 16. In this manner, 260 mg (89% of theory) of the Boc-protected intermediate tert-butyl 4-[3-({4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}carbamoyl)-5-(pentafluoro-λ6-sulphanyl)-phenyl]piperazine-1-carboxylate were obtained. This compound was dissolved in 3 ml of 1,4-dioxane and 1 ml of methanol, 0.31 ml (1.24 mmol) of a 4 M solution of hydrogen chloride in 1,4-dioxane was added and the mixture was stirred at 80° C. for 1 h. The mixture was then concentrated under reduced pressure and the residue was purified by preparative HPLC (Method 18). The product fractions were concentrated and the residue was dissolved in ethyl acetate and washed successively with saturated potassium carbonate solution and saturated sodium chloride solution. The organic phase was dried over sodium sulphate, filtered and concentrated under reduced pressure. Drying of the residue gave 155 mg (62% of theory) of the title compound.
후처리
- customwere obtained
- concentrationThe mixture was then concentrated under reduced pressure
- customthe residue was purified by preparative HPLC (Method 18)
- concentrationThe product fractions were concentrated
- dissolutionthe residue was dissolved in ethyl acetate
- washwashed successively with saturated potassium carbonate solution and saturated sodium chloride solution
- dry with materialThe organic phase was dried over sodium sulphate
- filtrationfiltered
- concentrationconcentrated under reduced pressure
- customDrying of the residue
출처 및 근거
- ORD 기록
- ord-ab86ac06e4c04ce5bd3d7695349ecd19
- 출처 데이터셋
- uspto-grants-2016_07
- 특허 번호
- US09394309B2
반응 노트
불러오는 중…